Cargando…
Safety of biologics in inflammatory bowel disease patients with COVID-19
BACKGROUND: Patients with Inflammatory bowel disease (IBD) remain highly concerned that either their disease or medications—namely, biologics—may increase the risk of severe coronavirus-2019 (COVID-19). We aimed to assess the safety of biologics in Inflammatory bowel disease (IBD) patients with COVI...
Autores principales: | Weissman, Simcha, Aziz, Muhammad, Smith, Wade-Lee, Elias, Sameh, Swaminath, Arun, Feuerstein, Joseph D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205311/ https://www.ncbi.nlm.nih.gov/pubmed/34131784 http://dx.doi.org/10.1007/s00384-021-03977-9 |
Ejemplares similares
-
Fr501 BIOLOGICS AND COVID-19 OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Weissman, Simcha, et al.
Publicado: (2021) -
Increased Mortality and Healthcare Costs Upon Hospital Readmissions of Ulcerative Colitis Flares: A Large Population-Based Cohort Study
por: Weissman, Simcha, et al.
Publicado: (2021) -
Quality measures in endoscopy: A systematic analysis of the overall scientific level of evidence and conflicts of interest
por: Weissman, Simcha, et al.
Publicado: (2022) -
Acrodermatitis Enteropathica Associated With Inflammatory Bowel Disease
por: Weissman, Simcha, et al.
Publicado: (2019) -
SARS-CoV-2 and Acute Diverticulitis: the Expanding Gastrointestinal Manifestations of COVID-19 Infection
por: Weissman, Simcha, et al.
Publicado: (2021)